Erythropoiesis-stimulating agents--time for a reevaluation.
Unger
Ellis F
EF
Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Thompson
Aliza M
AM
Blank
Melanie J
MJ
Temple
Robert
R
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology*; D000068256:Darbepoetin alfa; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006454:Hemoglobins; D006801:Humans; D011994:Recombinant Proteins; D051436:Renal Insufficiency, Chronic / Q000150:complications*
D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa